title: Bone mass at final height in precocious puberty after gonadotropin-releasing hormone agonist with and without calcium supplementation.
abstract: The aim of our longitudinal study was to evaluate bone mass in girls affected by central precocious puberty (CPP) that have reached final height, treated with GnRH agonist triptorelin (GnRHa), with or without calcium supplementation. We studied 48 Caucasian females affected by CPP (age at diagnosis, 7.19 +/- 0.96 yr), randomly assigned to two groups: group A (n = 21) treated with GnRHa and group B (n = 27) treated with GnRHa plus calcium gluconolactate and carbonate (1 g calcium/day in two doses) for at least 2 yr. Auxological parameters (standing height, weight, body mass index) and bone mineral density (BMD) at the lumbar spine [L2-L4, anteroposterior (AP)-BMD; lateral BMD; volumetric (v)BMD)] by dual-energy x-ray absorptiometry were evaluated at the beginning [chronological age (CA), 7.29 +/- 0.91 yr; bone age (BA), 8.80 +/- 1.24 yr] and end of treatment (CA, 11.27 +/- 0.97 yr; BA, 12.35 +/- 0.43 yr) and at final height (CA, 16.17 +/- 1.9 yr; BA, 16.93 +/- 0.98 yr, in each case >15 yr). Total bone mineral content, total BMD, and fat percentage were evaluated at the end of the study period using dual-energy x-ray absorptiometry. Final height was significantly higher than predicted height at diagnosis (159.9 +/- 6.3 cm vs. 152.9 +/- 9.6 cm; P < 0.05). Body mass index and fat percentage were not statistically different from control values. Densitometric values at final evaluation in groups A and B together were lower than in controls, but the differences were not statistically significant. The vBMD was significantly higher in group B than in group A at the end of treatment period (0.213 +/- 0.022 g/cm(3) vs. 0.192 +/- 0.021 g/cm(3); P < 0.01) and at final evaluation (0.246 +/- 0.023 g/cm(3) vs. 0.227 +/- 0.024 g/cm(3); P < 0.05). The percentage change (Delta%) between the start and end of treatment period in AP-BMD and vBMD was significantly higher in group B than in group A (Delta% AP-BMD: 20.36% +/- 1.10% vs. 16.16% +/- 1.90%, P < 0.01; Delta% vBMD: 19.08% +/- 3.52% vs. 9.26% +/- 5.15%; P < 0.01) and also between the start of treatment and final evaluation (Delta% AP-BMD: 61.23% +/- 1.61% vs. 56.97% +/- 1.45%, P < 0.01; Delta% vBMD: 36.69% +/- 5.01% vs. 28.01% +/- 5.76%, P < 0.01). In all our females with CPP treated with GnRHa, bone densitometric parameters were in the normal range for age and sex. However, bone mass achievement seemed to be better preserved in the group of patients supplemented with calcium.
authors.affiliation: Pediatric Clinic, University of Verona I-37134, Italy. franco.antoniazzi@univr.it
authors.forename: Franco
authors.initials: F
authors.lastname: Antoniazzi
authors.forename: Giorgio
authors.initials: G
authors.lastname: Zamboni
authors.forename: Francesco
authors.initials: F
authors.lastname: Bertoldo
authors.forename: Silvana
authors.initials: S
authors.lastname: Lauriola
authors.forename: Fabio
authors.initials: F
authors.lastname: Mengarda
authors.forename: Angelo
authors.initials: A
authors.lastname: Pietrobelli
authors.forename: Luciano
authors.initials: L
authors.lastname: Tatò
mesh_terms: D001827:Body Height; D015992:Body Mass Index; D015519:Bone Density / Q000187:drug effects*; D002136:Calcium, Dietary / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D019587:Dietary Supplements; D006801:Humans; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000378:metabolism; D017329:Triptorelin Pamoate / Q000627:therapeutic use*
chemical_list: D002136:Calcium, Dietary; D017329:Triptorelin Pamoate